Mihriban Tuna is the founder of Immutrin. Immutrin has raised $87M in total funding. Latest round: Series A. Backed by Cambridge Innovation Capital.
Mihriban Tuna is the Chief Executive Officer of Immutrin, a Bio-incubator company focused on developing a next-generation antibody therapy for ATTR amyloidosis. The company recently closed a £65 million Series A financing round to advance its lead antibody candidate through clinical proof of concept. Immutrin's approach aims to actively remove pre-existing amyloid deposits from tissues.
Full founder directory · Investor directory · Company funding database · Fundraising library